Kevin J Clerkin1, Donna M Mancini2, Josef Stehlik3, Wida S Cherikh4, Lars H Lund5. 1. Department of Medicine, Division of Cardiology, Columbia University College of Physicians and Surgeons, New York, New York. 2. Department of Medicine, Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York. 3. Department of Medicine, Division of Cardiology, University of Utah School of Medicine, Salt Lake City, Utah. 4. United Network for Organ Sharing, Richmond, Virginia. 5. Department of Medicine, Karolinska Institutet & Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.
Abstract
BACKGROUND: Continuous-flow mechanical circulatory support (CF-MCS) is associated with impaired vascular function and increased risk of vasoplegia. One contributing factor to early graft failure (EGF) is severe vasoplegia. We tested the hypothesis that CF-MCS is associated with increased risk of EGF. METHODS: Adult primary heart transplant recipients in the ISHLT Registry from 2005 to 2013 were stratified into three groups based on pre-transplant MCS: No MCS (n = 11 748), pulsatile (P)-MCS (n = 718), and CF-MCS (n = 3818). EGF was defined as death/retransplantation due to graft failure within 30 days after HT. Comparisons were made using descriptive statistics and associations. EGF was assessed with multivariable Cox proportional hazard regression. RESULTS: The incidence of EGF within 30 days was similar between groups (No MCS 2.2%, P-MCS 3.3%, CF-MCS 2.1%, P = .10). Following multivariable adjustment, the risk of EGF was not statistically different for those with CF-MCS compared with P-MCS (HR 0.75, 95% CI 0.46-1.21, P = .24). The risk of EGF was numerically, but not statistically significantly higher for CF-MCS compared with No MCS (HR 1.24, 95% CI 0.92-1.67, P = .16). CONCLUSION: CF-MCS use was not associated with a statistically significant increased risk of EGF resulting in death or retransplantation in the first 30 days after transplant.
BACKGROUND: Continuous-flow mechanical circulatory support (CF-MCS) is associated with impaired vascular function and increased risk of vasoplegia. One contributing factor to early graft failure (EGF) is severe vasoplegia. We tested the hypothesis that CF-MCS is associated with increased risk of EGF. METHODS: Adult primary heart transplant recipients in the ISHLT Registry from 2005 to 2013 were stratified into three groups based on pre-transplant MCS: No MCS (n = 11 748), pulsatile (P)-MCS (n = 718), and CF-MCS (n = 3818). EGF was defined as death/retransplantation due to graft failure within 30 days after HT. Comparisons were made using descriptive statistics and associations. EGF was assessed with multivariable Cox proportional hazard regression. RESULTS: The incidence of EGF within 30 days was similar between groups (No MCS 2.2%, P-MCS 3.3%, CF-MCS 2.1%, P = .10). Following multivariable adjustment, the risk of EGF was not statistically different for those with CF-MCS compared with P-MCS (HR 0.75, 95% CI 0.46-1.21, P = .24). The risk of EGF was numerically, but not statistically significantly higher for CF-MCS compared with No MCS (HR 1.24, 95% CI 0.92-1.67, P = .16). CONCLUSION: CF-MCS use was not associated with a statistically significant increased risk of EGF resulting in death or retransplantation in the first 30 days after transplant.
Authors: Koji Takeda; Boyangzi Li; Arthur R Garan; Veli K Topkara; Jiho Han; Paolo C Colombo; Maryjane A Farr; Yoshifumi Naka; Hiroo Takayama Journal: J Heart Lung Transplant Date: 2016-12-23 Impact factor: 10.247
Authors: Helen L Thomas; Vamsidhar B Dronavalli; Jayan Parameshwar; Robert S Bonser; Nicholas R Banner Journal: Eur J Cardiothorac Surg Date: 2011-04-14 Impact factor: 4.191
Authors: Lars H Lund; Leah B Edwards; Anne I Dipchand; Samuel Goldfarb; Anna Y Kucheryavaya; Bronwyn J Levvey; Bruno Meiser; Joseph W Rossano; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2016-08-21 Impact factor: 10.247
Authors: Offer Amir; Branislav Radovancevic; Reynolds M Delgado; Biswajit Kar; Rajko Radovancevic; Maria Henderson; William E Cohn; Frank W Smart Journal: J Heart Lung Transplant Date: 2006-02-03 Impact factor: 10.247
Authors: T Nishimura; E Tatsumi; S Takaichi; Y Taenaka; Y Wakisaka; T Nakatani; T Masuzawa; Y Takewa; M Nakamura; S Endo; Y S Sohn; H Takano Journal: ASAIO J Date: 1997 Sep-Oct Impact factor: 2.872
Authors: Javier Segovia; M Dolores G Cosío; Juan M Barceló; Manuel Gómez Bueno; Pablo García Pavía; Raúl Burgos; Santiago Serrano-Fiz; Carlos García-Montero; Evaristo Castedo; Juan Ugarte; Luis Alonso-Pulpón Journal: J Heart Lung Transplant Date: 2011-04-05 Impact factor: 10.247
Authors: Lauren B Cooper; Robert J Mentz; Leah B Edwards; Amber R Wilk; Joseph G Rogers; Chetan B Patel; Carmelo A Milano; Adrian F Hernandez; Josef Stehlik; Lars H Lund Journal: J Heart Lung Transplant Date: 2016-07-17 Impact factor: 10.247
Authors: David W Markham; Qi Fu; M Dean Palmer; Mark H Drazner; Dan M Meyer; Brian T Bethea; Jeffrey L Hastings; Naoki Fujimoto; Shigeki Shibata; Benjamin D Levine Journal: Circ Heart Fail Date: 2012-12-18 Impact factor: 8.790
Authors: Markus C Elze; John Gregson; Usman Baber; Elizabeth Williamson; Samantha Sartori; Roxana Mehran; Melissa Nichols; Gregg W Stone; Stuart J Pocock Journal: J Am Coll Cardiol Date: 2017-01-24 Impact factor: 24.094